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Gestational diabetes mellitus (GDM) is characterized by insulin resistance accompanied 
by low/absent beta-cell compensatory adaptation to the increased insulin demand. 
Although the molecular mechanisms and factors acting on beta-cell compensatory 
response during pregnancy have been partially elucidated and reported, those inducing 
an impaired beta-cell compensation and function, thus evolving in GDM, have yet to be 
fully addressed. MicroRNAs (miRNAs) are a class of small endogenous non-coding RNAs, 
which negatively modulate gene expression through their sequence-specific binding to 
3′UTR of mRNA target. They have been described as potent modulators of cell survival 
and proliferation and, furthermore, as orchestrating molecules of beta-cell compensatory 
response and function in diabetes. Moreover, it has been reported that miRNAs can 
be actively secreted by cells and found in many biological fluids (e.g., serum/plasma), 
thus representing both optimal candidate disease biomarkers and mediators of tissues 
crosstalk(s). Here, we analyzed the expression profiles of circulating miRNAs in plasma 
samples obtained from n =  21 GDM patients and from n =  10 non-diabetic control 
pregnant women (24–33 weeks of gestation) using TaqMan array microfluidics cards 
followed by RT-real-time PCR single assay validation. The results highlighted the upreg-
ulation of miR-330-3p in plasma of GDM vs non-diabetics. Furthermore, the analysis 
of miR-330-3p expression levels revealed a bimodally distributed GDM patients group 
characterized by high or low circulating miR-330 expression and identified as GDM-
miR-330high and GDM-miR-330low. Interestingly, GDM-miR-330high subgroup retained 
lower levels of insulinemia, inversely correlated to miR-330-3p expression levels, and 
a significant higher rate of primary cesarean sections. Finally, miR-330-3p target genes 
analysis revealed major modulators of beta-cell proliferation and of insulin secretion, 
such as the experimentally validated genes E2F1 and CDC42 as well as AGT2R2, a 
gene involved in the differentiation of mature beta-cells. In conclusion, we demonstrated 
that plasma miR-330-3p could be of help in identifying GDM patients with potential 
worse gestational diabetes outcome; in GDM, miR-330-3p may directly be transferred 
from plasma to beta-cells thus modulating key target genes involved in proliferation, 
differentiation, and insulin secretion.
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inTrODUcTiOn
Gestational diabetes mellitus (GDM) is defined as any degree of 
carbohydrate intolerance, with onset or first recognition during 
second or third trimester of pregnancy (1). The prevalence in 
the world is increasing, and approximately 7% of all pregnancies 
are complicated by GDM (1), with major risk factors identified 
in previous history of GDM, history of macrosomia, familiarity 
for type 2 diabetes (T2D), elevated maternal age, and pre-
pregnancy obesity (2, 3).
The pathophysiology of GDM is still not fully characterized. 
The inadequate β-cell adaptation to peripheral insulin resistance, 
characterizing second and third trimesters of gestation, is likely 
to be the main cause of GDM, even though the molecular mecha-
nisms of such failure are mostly unknown (4). During normal 
pregnancy, glucose homeostasis is maintained by a compensatory 
increase in insulin secretion, associated with hypertrophy and/or 
hyperplasia of β-cells (5): it is supposed that several molecules, 
like placental hormones, play a central role in these adaptive 
changes (6), thus contributing to gene expression changes neces-
sary to beta-cells in order to fulfill the compensatory request. 
Moreover, such compensatory phenomenon involves several 
specific beta-cell factors acting downstream these signaling 
molecules, such as the transcription factors MAFA and/or 
PDX1 whose expression strengthen and characterizes beta-cell 
phenotype maintenance (7, 8).
MicroRNAs (miRNAs) are endogenous ~19–24  nt small 
non-coding RNAs that play an important role in the modulation 
of gene expression (9). Indeed, through base pairing to partially 
complementary sites in the untranslated region of mRNAs, 
miRNAs can negatively modulate expression and translation of 
these molecules (10), thus being key factors in gene expression 
regulation. Each miRNA can potentially modulate multiple genes, 
whereas a single gene can be targeted by several miRNAs (11). 
Such complexity justifies the implication of miRNAs in virtually 
every cellular process, as well as in development or differentia-
tion, regulation of cell cycle (12), and immune system homeo-
stasis (13). Furthermore, miRNAs have been demonstrated to be 
involved in multiple sides of beta-cell function and differentiation 
(14), both in normal and diabetic conditions, as well as in beta-
cell compensatory process during pregnancy.
Despite their function as regulators of gene expression, 
recent studies demonstrated that miRNAs are not exclusively 
intracellular, but also extracellular, being present in a cell-free 
circulating form in many different biological fluids, including 
serum or plasma (15). These miRNAs can be associated with 
proteins (vesicles-free) or held inside membranous vesicles such 
as shedding vesicles or exosomes. Importantly, extracellular 
circulating miRNAs have been found aberrantly expressed in 
the bloodstream during the course of many diseases (16), and 
some evidences suggested a potential role for miRNAs in cell–cell 
communication during pathological processes, particularly those 
packaged onto exosomes (17, 18). Furthermore, a putative use 
of circulating miRNAs as diagnostic, prognostic, and therapeutic 
biomarkers of many different diseases, have been strongly sug-
gested, as they can be easily detected and measured from body 
fluids (19).
Recently, several studies have evaluated the expression of 
circulating miRNAs (plasma/serum) in diabetes, suggesting 
their putative use as early biomarkers of this group of chronic 
metabolic diseases (20). As a matter of fact, circulating miRNAs 
have been associated with β-cell mass and function and with 
immune system homeostasis, that certainly represent major 
players in diabetes pathogenesis (21–23). Regarding GDM, there 
is a paucity of data defining the expression and the diagnostic 
utility of circulating miRNAs in this important complication of 
pregnancy (24). Surely, the understanding of miRNAs function 
could improve knowledge about etiology and pathophysiology 
of GDM, while the characterization of circulating miRNAs 
expression could represent an important tool in order to diagnose 
GDM earlier than current methods (25). To the time of writing, 
only two groups have investigated the expression of circulating 
miRNAs in diabetic and non-diabetic pregnant women using 
high-throughput technologies. Zhao et  al. have evaluated 
miRNAs profiling in serum collected at 16th–19th gestational 
weeks: three miRNAs (miR-132, miR-29a, and miR-222) were 
significantly decreased in GDM pregnant women with respect 
to the controls (CTR) (26). Similarly, Zhu et al. have evaluated 
miRNAs expression in plasma collected at 16th–19th gestational 
weeks: five miRNAs (hsa-miR-16-5p, hsa-miR-17-5p, hsa-miR-
19a-3p, hsa-miR-19b-3p, and hsa-miR-20a-5p) were upregulated 
in diabetic pregnant women with respect to CTR (27). Although 
informative, the results of these two studies are discordant, prob-
ably due to the different samples analyzed (serum vs plasma) and 
to the different procedures used.
Due to the paucity of data on circulating miRNAs in GDM 
and to the presence of discordant data, we aimed at evaluating 
circulating miRNAs expression profiles in plasma of diabetic 
vs non-diabetic pregnant women during the third trimester of 
gestation, with the final goal to identify new potential diagnostic/
prognostic GDM biomarkers as well as to potentially elucidate 
part of the complex mechanisms involved in the onset of GDM.
MaTerials anD MeThODs
Patients and Blood samples
The patients were recruited in the Diabetes out-patient Unit in 
Siena University Hospital. All the patients performed a 75-g 
oral glucose tolerance test at 16–19  weeks or 24–28  weeks of 
pregnancy, and GDM was diagnosed if one of the three glucose 
concentrations measured was above the cutoff values (fasting 
plasma glucose ≥5.1  mmol/l; 1-h plasma glucose ≥10  mmol/l; 
2-h plasma glucose ≥8.5 mmol/l), according to Italian guidelines. 
Peripheral blood samples were collected from 21 women with 
GDM and 10 pregnant non-diabetic CTR at 24–33 weeks of preg-
nancy to evaluate miRNAs expression and laboratory parameters 
(glycemia, cholesterol, triglycerides, insulin levels, HbA1c, creati-
nine, urinary albumin, osteocalcin, 25-OH vitamin D, calcitonin, 
and serum calcium). Moreover, during the third trimester of 
pregnancy, all the 31 participants performed an obstetric echog-
raphy to evaluate fetal parameters (biparietal diameter, cranial 
circumference, abdominal circumference, femur length, and 
fetal weight). Patients’ main clinical parameters are reported and 
TaBle 1 | Clinical characteristics (maternal and fetal) of the study population.
clinical parameter micrornas profiling cohort Validation cohort
non-diabetic pregnant patients (n = 4) gDM patients (n = 4) non-diabetic pregnant patients (n = 10) gDM patients (n = 21)
Maternal characteristics
Age (years) 35.25 ± 3.86 35.00 ± 3.91 32.80 ± 5.16 35.57 ± 5.63
BMI (kg/m2) 20.40 ± 0.77 21.75 ± 1.11 22.85 ± 3.46 25.25 ± 4.00
Glycemia (mg/dl) 67.00 ± 0.00 80.00 ± 2.16* 69.33 ± 8.35 80.32 ± 7.64**
Insulinaemia (mUI/ml) 4.30 ± 0.69 10.85 ± 4.05* 7.36 ± 3.29 11.84 ± 6.03**
HbA1c (%) 4.76 ± 0.32 5.175 ± 0.15 4.94 ± 0.26 5.19 ± 0.32
Total cholesterol (mg/dl) 267.00 ± 58.50 276.75 ± 79.81 259.75 ± 39.47 271.84 ± 53.65
Triglycerides (mg/dl) 187.33 ± 63.32 160.75 ± 18.12 173.87 ± 59.75 218.21 ± 57.42
Urinary Albumin (mg/l) 4.40 ± 2.94 2.67 ± 0.65 7.378 ± 10.334 16.60 ± 54.97
Creatinine (mg/dl) 0.52 ± 0.11 0.55 ± 0.08 0.56 ± 0.07 0.53 ± 0.07
Osteocalcin (ng/ml) 21.27 ± 2.82 15.07 ± 4.26 18.86 ± 3.93 14.53 ± 3.50
25-(OH)D3 (ng/ml) 16.20 ± 3.16 20.77 ± 6.70 17.76 ± 8.38 17.54 ± 7.82
Calcitonin (pg/ml) 1.57 ± 1.52 3.67 ± 4.99 1.73 ± 1.92 3.02 ± 3.07
Ca++ (mg/dl) 8.74 ± 0.18 9.35 ± 0.46 8.72 ± 0.21 9.01 ± 0.37
Fetal characteristics
FW (g) 2,274.00 ± 311.19 2,167.08 ± 302.23 2,126.50 ± 406.12 2,050.37 ± 238.29
FBD (mm) 86.40 ± 2.71 79.20 ± 2.45 84.16 ± 3.98 82.34 ± 2.97
FHC (mm) 310.52 ± 16.66 304.22 ± 15.75 304.87 ± 16.08 300.82 ± 8.49
FAC (mm) 296.97 ± 11.00 285.65 ± 19.13 288.27 ± 17.26 284.63 ± 13.42
FFL (mm) 65.25 ± 2.18 61.77 ± 5.64 63.57 ± 3.77 63.53 ± 3.36
FW, fetal weight; FBD, fetal biparietal diameter; FHC, fetal head circumference; FAC, fetal abdominal circumference; FFL, fetal femur length; GDM, gestational diabetes mellitus. Data 
are reported as mean ± SD.
*p < 0.05 GDM vs non-diabetic pregnant patients (profiling cohort).
**p < 0.05 GDM vs non-diabetic pregnant patients (validation cohort).
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summarized in Table 1. This study was carried out in accordance 
with the required local ethical recommendations. All procedures 
followed were in accordance with the ethical standards of the 
responsible committee on human experimentation (institutional 
and national) and with the Helsinki Declaration of 1975, as 
revised in 2013. Informed consent was obtained from all patients 
for being included in the study.
Blood samples Processing
The blood samples were processed according to a standardized 
operating procedure to collect plasma for miRNAs analysis. The 
blood was drawn in BD Vacutainer K2-EDTA tubes and processed 
within 2 h from collection.
The whole blood was separated into plasma and cellular frac-
tions by centrifugation at 1,800g for 10 min at room temperature; 
plasma was collected in RNAse-free tubes and further centrifuged 
at 1,200g for 20 min at 10°C to completely remove contaminant 
cells. Finally, plasma samples were aliquoted to avoid freeze–thaw 
cycles and finally stored at −80°C up to the RNA extraction.
rna extraction
Plasma samples were thawed on ice and then further centrifuged 
3,000g for 5 min at 4°C in order to completely remove cell debris. 
MiRNeasy miRNA extraction kit (Qiagen, Hilden, Germany) 
was used to extract RNA from 50 µl of plasma from each patient, 
by adding 1,200 µl of Trizol LS (Lifetechnologies, CA, USA) and 
finally eluted in 30 µl of nuclease-free water. Moreover, 25 pmol of 
the spike-in control ath-miR-159a were added to each sample, in 
order to control variations in RNA extraction procedures.
TaqMan mirna array Profiling analysis
TaqMan miRNA Human Array Panel A platform (Lifetechno-
logies, CA, USA) was adopted to profile the expression the 
expression of 384 miRNAs in as low as 50 µl of plasma, follow-
ing manufacturer’s instructions. RNA was reverse-transcribed 
using “Megaplex RT primers Pool-A” (Lifetechnologies, CA, 
USA); briefly, 3 µl of extracted RNA from 50 µl of each plasma 
sample were added to 0.80  µl of 10× Megaplex RT Primers, 
0.20 µl of 100 mM dNTPs, 1.50 µl of 50 U/μl Multiscribe RT, 
0.80 µl of 10× RT Buffer, 0.90 µl of 25 mM MgCl2, 0.10 µl of 
20 U/μl RNAse Inhibitor, and 0.20 µl of H2O. The product of this 
reaction was incubated for 40 cycles at 16°C for 2 min, 42°C for 
1 min, and 50°C for 1 s, and then at 85°C for 5 min. Afterward, 
the synthesized cDNA was preamplified using “Megaplex 
Preamp primers Pool-A”: 2.5 µl of cDNA from each sample were 
added to 12.5 µl of 2× TaqMan Preamp Master Mix, 2.5 µl of 
10× Preamp Primers A V.2.1, and 7.5 µl of H2O. The product 
of this reaction was incubated at 95°C for 10 min, at 55°C for 
2 min, and at 72°C for 2 min, then for 12 cycles at 95°C for 15 s 
and 60°C for 4  min and, finally, at 99°C for 10  min. Finally, 
preamplified cDNA was diluted 1:4 in 0.1× Tris-EDTA pH8.0 
to obtain a final volume of 100 µl.
The reaction mix for each microfluidic card was prepared add-
ing 360 µl of H2O and 450 µl of TaqMan Universal PCR Master 
Mix 2× to 90 µl of diluted and preamplified cDNA. The product 
of this reaction was incubated at 95°C for 10 min, followed by 
40 cycles of 95°C for 15  s and 60°C for 1  min. The real-time 
PCR instrument ViiA7 (Lifetechnologies, CA, USA) was used to 
perform the reactions.
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Resulting data were analyzed and exported using Expression 
Suite 1.2.1 software (Lifetechnologies, CA, USA). Analysis was 
performed by using 2−ΔΔCt method following normalization 
with both Global Mean Normalization method and Norm-
Finder search for most stable endogenous miRNAs (miR-374, 
miR-320).
Hierarchical clustering analysis plot was computed in order 
to obtain a global view of miRNAs expression levels among 
eight plasma samples analyzed and to identify clustered group 
of miRNAs. Differentially expressed miRNAs were identified by 
performing a volcano plot analysis by applying a cutoff fold change 
of 2.0 and a statistical cutoff of p < 0.05 using Student’s t test and 
Mann–Whitney statistical non-parametrical U test. Hierarchical 
Clustering analysis plot and Volcano Plot were elaborated using 
Spotfire 5.0 (Tibco) and GraphPad 6.0, respectively.
single assay qrT real-time Pcr
The expression of miRNAs miR-330-3p and miR-548c was 
analyzed in all the 31 plasma samples through single assay 
qRT real-time PCR using TaqMan miRNA assay primers 
(Lifetechnologies, CA, USA). RNA was reverse-transcribed using 
“Megaplex RT primers Pool-A” protocol and preamplified using 
“Megaplex Preamp primers Pool-A” (see above). In each well, 
5 µl of preamplified cDNA (diluted 1:40) were added to 15 µl of 
reaction mix composed of 10 µl TaqMan Universal Master Mix, 
1 µl of TaqMan miRNA expression assay, 4 µl of H2O. The reac-
tion was incubated at 95°C for 10 min, followed by 40 cycles of 
95°C for 15 s and 60°C for 1 min. Data analysis was performed by 
using 2−ΔCt method; samples with resulting raw cycle-threshold 
(Ct) >35.0 were considered as not detected/expressed. miRNAs 
miR-320 and miR-374a were adopted to normalize the values of 
detected miRNAs of interest.
statistical analysis
Differences in expression levels of miRNAs, in clinical charac-
teristics (age, BMI), in laboratory parameters and in obstetric 
parameters were evaluated by Student’s t test, non-parametric 
Mann–Whitney U test or Fisher’s Exact test. The correlation 
between expression levels of hsa-miR-330-3p and insulin levels 
was evaluated by Spearman non-parametric test. A p-value < 0.05 
was considered as statistically significant. GraphPad 5.1 was 
adopted for statistical analysis of the data.
Target genes identification and 
Bioinformatic analysis
In order to retrieve predicted or previously experimentally vali-
dated miRNAs target genes, we used Targetscan Human 7.01 (28) 
and miRTarbase2 (29), respectively.
Interaction network analysis was performed by using BioGRID 
3.4 tool3 (30) in order to verify all the potential interactions of 
identified target genes and potentially function mediators.
1 http://www.targetscan.org/vert_71/.
2 http://mirtarbase.mbc.nctu.edu.tw/.
3 http://thebiogrid.org.
resUlTs
Plasma mirnas expression Profiles  
in gDM Patients
In an attempt to verify the potential altered expression of cir-
culating miRNAs in plasma of GDM patients, we performed an 
unbiased TaqMan Array profiling by analyzing 384 miRNAs in 
a discovery cohort composed of plasma samples derived from 
n = 4 non-diabetic pregnant women (24–33 weeks of gestation; 
age 35.25 ± 3.86 years; BMI 20.40 ± 0.77 kg/m2) and n = 4 GDM 
patients (24–28 weeks of gestation; age 35.00 ± 3.9 years; BMI 
21.5 ±  1.11  kg/m2) (Table  1—profiling cohort). A total of 202 
miRNAs were detected (raw Ct cutoff < 35.0) in at least one sam-
ple/group, with a global mean miRNAs detection rate between 
40 and 50% (Figure S1A in Supplementary Material). Since 
global mean normalization strategy for miRNAs expression data 
analysis has been indicated as the most reliable method to detect 
changes in circulating miRNA expression levels, we adopted such 
strategy to analyze resulting raw data; indeed such approach 
showed a good degree of stability across samples. However, in 
order to detect single miRNAs which can be reliably used as 
plasma miRNA normalization factors for subsequent single assay 
validation stage, we looked for two most stable plasma miRNAs 
among 202 detected across the eight samples analyzed; using the 
algorithm NormFinder, we identified miR-320 and miR-374a as 
the most stably expressed miRNAs (Figure S1C in Supplementary 
Material) and with comparable stability respect to the global 
mean normalization.
Overall, resulting data are reported in the hierarchical clus-
tering heatmap analysis showing the expression levels of detected 
miRNAs analyzed using global mean normalization (Figure 1A). 
Since our aim was to identify potential miRNAs expression altera-
tions in plasma of GDM patients respect to non-diabetic CTR, 
adopting a specific fold change (2.0-fold change upregulated/
downregulated vs non-diabetics) and p-value cutoffs (p <  0.05 
Student’s t-test on normally distributed ΔCt), we detected the 
differential expression of four miRNAs, as demonstrated by 
Volcano Plot analysis (Figure 1B). Namely, we identified miR-
330-3p and miR-483-5p (upregulated in GDM vs non-diabetic 
subjects) and miR-548c-3p and miR-532-3p (downregulated 
in GDM vs non-diabetic subjects) (Figures  1B,C). As shown 
in Volcano plot, miR-330-3p and miR-548c-3p resulted the 
most differentially expressed miRNAs in GDM vs non-diabetic 
pregnant women (miR-330-3p: 11.1-fold increase; miR-548c-3p: 
25.3-fold decrease; miR-483-5p: 2.01-fold increase; miR-532-3p: 
2.1-fold decrease) and then taken into consideration for further 
analyses involving a second patients cohort.
Stem-loop RT-real-time PCR was adopted to perform single 
assay validation analysis of miRNAs miR-330-3p and miR-
548c-3p. Such validation analysis was performed by including a 
second cohort of patients, composed of additional samples from 
non-diabetic and GDM patients (Table  1—validation cohort). 
Therefore, the expression of such miRNAs were finally evaluated 
in a total of n = 10 non-diabetic pregnant women and n = 21 
GDM patients. The results highlighted a significant increased 
expression of miR-330-3p (p = 0.01, Mann–Whitney U test) in 
plasma of GDM vs non-diabetic subjects (Figure 2A) while no 
FigUre 1 | Taqman microRNAs (miRNAs) Array profiling in plasma of gestational diabetes mellitus (GDM) patients. (a) Hierarchical Clustering Heatmap analysis of 
miRNAs detected in at least one sample/group. n = 4 non-diabetic controls (CTR) and n = 4 GDM patients are reported. miRNAs expression levels are reported as 
scale colors based on dCT expression [blue (high expression): dCT = −13.7; red (low expression): dCT = 13.6; grey (not detected)]. (B) Volcano plot analysis 
showing differentially expressed miRNAs; single black dot represents miRNAs positioned based on the relative fold change and p-values. Fold change cutoff (red 
lines) was set at 2.0-fold while p-values cutoff (blue line) was set at 0.05 based on Student’s t-test on normally distributed dCT. (c) Results reported as dot plot 
graph showing miRNAs differentially expressed; extrapolated values from Taqman array profiling are reported as normalized 2−dCT together with mean ± SEM and 
p-values further elaborated using non-parametric Mann–Whitney U test (p < 0.05).
FigUre 2 | RT-PCR Single assay validation of miR-330-3p and miR-548c-3p. Single assay RT-real-time PCR validation of (a) miR-330-3p and (B) miR-548c-3p on 
n = 10 non-diabetic controls (CTR) and n = 21 gestational diabetes mellitus (GDM) patients. Red dots represent the discovery cohort analyzed in the miRNA 
profiling stage while the black dots represent the validation cohort. Data are reported as normalized 2−dCT values together with mean ± SEM. Mann–Whitney U test, 
p < 0.05.
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significant differences were observed in miR-548c-3p expression 
levels (Figure 2B).
Plasma levels of mir-330-3p Define  
Two gDM Patient subgroups
Interestingly, by analyzing miR-330-3p expression data, we 
detected a clear-cut separation within GDM patients group, 
characterized by n = 11 patients with high miR-330-3p expres-
sion (GDM miR-330high) and n = 10 GDM patients with low/null 
miR-330-3p expression (GDM miR-330low) (Figure  3A); miR-
330-3p levels significantly differed between the two subgroups 
and respect to non-diabetic subjects as well (Figure 3B). Based on 
miR-330-3p expression, GDM patients group resulted bimodally 
distributed, thus clearly distinguishing two GDM subgroups.
TaBle 2 | Clinical characteristics (maternal and fetal) of the study population subgrouped based on plasma miR-330-3p expression.
clinical parameters non-diabetic pregnant patients (n = 10) mir-330high gDM patients (n = 11) mir-330low gDM patients (n = 10)
Maternal characteristics
Age (years) 32.80 ± 5.16 36.55 ± 5.48 34.50 ± 5.87
BMI (kg/m2) 22.85 ± 3.46 24.90 ± 4.55 25.64 ± 3.49
Glycemia (mg/dl) 69.33 ± 8.35 81.18 ± 6.89 79.13 ± 8.90
Insulinaemia (mUI/ml) 7.36 ± 3.29 10.71 ± 6.09 13.40 ± 5.96
HbA1c (%) 4.94 ± 0.26 5.24 ± 0.35 5.13 ± 0.27
Total cholesterol (mg/dl) 259.75 ± 39.47 266.55 ± 58.89 279.13 ± 48.39
Triglycerides (mg/dl) 173.87 ± 59.75 207.91 ± 66.11 232.37 ± 42.89
Urinary albumin (mg/l) 7.378 ± 10.334 3.21 ± 1.89 35.01 ± 84.25
Creatinine (mg/dl) 0.56 ± 0.07 0.54 ± 0.06 0.52 ± 0.08
Osteocalcin (ng/ml) 18.86 ± 3.93 13.97 ± 3.89 14.96 ± 3.34
25-(OH)D3 (ng/ml) 17.76 ± 8.38 17.63 ± 7.24 17.44 ± 8.82
Calcitonin (pg/ml) 1.73 ± 1.92 2.67 ± 3.28 3.37 ± 2.99
Ca++ (mg/dl) 8.72 ± 0.21 9.14 ± 0.37 8.87 ± 0.34
Week of gestation at delivery (weeks) 39.80 ± 1.48 38.70 ± 1.41 39.50 ± 1.37
Fetal characteristics
FW (g) 2,126.50 ± 406.12 2,096.36 ± 279.25 1,987.13 ± 163.46
FBD (mm) 84.16 ± 3.98 82.79 ± 3.85 81.71 ± 0.84
FHC (mm) 304.87 ± 16.08 301.20 ± 10.15 300.29 ± 6.13
FAC (mm) 288.27 ± 17.26 287.94 ± 15.42 280.09 ± 9.09
FFL (mm) 63.57 ± 3.77 63.64 ± 3.84 63.39 ± 2.80
FW, fetal weight; FBD, fetal biparietal diameter; FHC: fetal head circumference; FAC, fetal abdominal circumference; FFL, fetal femur length; GDM, gestational diabetes mellitus. Data 
are reported as mean ± SD.
FigUre 3 | Plasma miR-330-3p identifies two subpopulations of gestational diabetes mellitus (GDM) patients. (a) Dot plot graphs depicting the expression of 
miR-330-3p, which identifies two different GDM subpopulations: miR-330high (blue rectangle), miR-330low (yellow rectangle). (B) Expression of plasma miR-330-3p in 
non-diabetic controls (CTR) (n = 10), GDM-miR-330high (n = 11), and GDM-miR-330low (n = 10). Data are reported as normalized 2−dCT values together with 
mean ± SEM. Mann–Whitney U test, p < 0.05.
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Such peculiar bimodal distribution within GDM patients led 
us to verify whether potential differences in clinical parameters, 
maternal diabetic outcomes, and/or fetal outcomes may occur 
between miR-330high and miR-330low GDM patients. First, no 
differences were detected between the two subgroups in terms 
of age and BMI (Table 2). Interestingly, we observed that insu-
linemia (measured at onset) was lower in miR-330high respect to 
miR-330low GDM patients (Table  2), while, as expected, both 
GDM subgroups retained higher levels of insulinemia respect 
to non-diabetic subjects. More importantly, we observed that 
the expression of circulating miR-330-3p in GDM patients, 
but not in non-diabetics, was significantly inversely correlated 
to insulinaemia (Figure 4A), as an increased expression of cir-
culating miR-330-3p resulted in lower insulinemia (p = 0.042) 
(Figure  4B). Correlation analysis of miR-548c-3p expression 
levels and insulinemia both in GDM and in non-diabetic subjects 
did not retrieve any significant results (Figures 4C,D).
Additionally, although not statistically significant, patients 
within GDM-miR-330high subgroup retained an higher rate of 
predisposing T2D genetic background, having at least one first-
degree relative affected by T2D and, furthermore, were more 
likely to require future insulin therapy respect to patients with 
low miR-330-3p expression (Table 3). Moreover, by measuring 
pregnancy outcomes, we observed a significant increased rate 
of cesarean sections in pregnant women within GDM-miR-
330high subgroup respect to GDM-miR-330low, due to advanced 
maternal age, previous cesarean sections and complications of 
pregnancy (e.g., maternal hydronephrosis, polyhydramnios, fetal 
FigUre 4 | miR-330-3p expression correlates with insulinemia in gestational diabetes mellitus (GDM) patients. Correlation analysis between miR-330-3p  
and miR-548c-3p expression levels, reported as normalized 2−dCT values, and insulinemia, reported as mUI/ml, in (a,c) non-diabetic controls (n = 8) and in  
(B,D) GDM patients (n = 21). Spearman R test was performed to evaluate r-values and p-values (p < 0.05).
TaBle 3 | Comparison between gestational diabetes mellitus (GDM) subgroups 
based on selected diabetic and pregnancy/pre-pregnancy outcomes.
gDM  
mir-330high (%)
gDM  
mir-330low (%)
p-Value
Insulin therapy 5/11 (55) 2/10 (20) 0.36
T2D first-degree relatives 6/11 (66) 2/10 (20) 0.18
Cesarean sections 8/11 (88) 1/10 (10) 0.0075
Non spontaneous 
conception
4/11 (44) 0/10 (0) 0.092
The following parameter are reported: requirement of insulin therapy during third 
trimester of gestation; differences in familiarity for type 2 diabetes (T2D) (evaluated in 
first-degree relatives); delivery through Cesarean section; conception through medically 
assisted procreation techniques (e.g., ICSI, IVF). The results are expressed both in 
number of the total and in percentage.
Italic font highlights significant p-values using Fisher’s exact test.
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of beta-cell function and proliferation machinery: E2F1 and 
CDC42 (Table 4) (31, 32). Both identified genes are involved 
in beta-cell growth and proliferation being activators of a 
series of proteins involved in cell cycle activation and cellular 
growth; interaction network analysis (Figures 5 and 6) shows 
all the previously dema consistent and significant number of 
interactions are toward factors highly involved in prolifera-
tion. However, the interaction network analysis revealed that 
several other interacting genes have been demonstrated to 
control beta-cell phenotype maintenance, such as KAT2B, 
CDH1, SIRT1, and PAK1 (Figures 5 and 6, highlighted in red). 
Furthermore, beside their role in cellular growth and prolif-
eration, both E2F1 and CDC42 have been also demonstrated 
to be involved in glucose-stimulated insulin secretion, being 
prevalently involved in first- and second-phase insulin release, 
respectively (33–36).
Finally, among predicted target genes, we identified other key 
factors, which could be involved in beta-cell proliferation and 
differentiation, thus potentially being negatively modulated by 
increased expression of miR-330-3p (Table 4).
DiscUssiOn
Circulating miRNAs have been suggested as potential biomark-
ers of several diseases being potentially secreted in biological 
fluids by virtually all cell types (44). Furthermore, they have 
macrosomia). This suggests a worse pregnancy outcome possibly 
due to a more aggressive diabetic phenotype characterized by 
increased circulating expression of miR-330-3p.
mir-330-3p Targets several genes 
involved in Beta-cell compensatory 
Process and in glucose homeostasis
An in depth analysis of the potential functions of miR-330-3p 
through the evaluation of its previously experimentally validated 
target genes, revealed that miR-330-3p targets two components 
TaBle 4 | MicroRNA miR-330-3p validated and predicted target genes.
Official symbol Official full name sequence accession iD Predicted/validated Function
E2F1 E2F transcription factor 1 NM_005225.2 Validated Overexpression of E2F1 can stimulate beta-cell proliferation  
activity. E2F1−/− mice have a reduced pancreatic size and are 
glucose intolerant due to impaired beta-cell proliferation
Involved in insulin secretion (36)
CDC42 Cell division cycle 42 NM_001039802.1 Validated Regulates signaling pathways that control several cellular functions 
including cell morphology, migration, endocytosis, and cell cycle 
progression. Depletion of Cdc42 from mouse isolated islets results  
in the selective loss of second-phase insulin release (35)
AGTR2 Angiotensin II receptor 
type 2
NM_000686.4 Predicted G-protein coupled receptor 1 family that functions as a receptor  
for angiotensin II. AGTR2 receptor is involved in beta-cell 
differentiation (37, 38)
TFEB Transcription Factor EB NM_001167827.2 Predicted Plays a central role in the signal transduction processes required  
for normal vascularization of placenta (39)
EIF4EBP2 Eukariotic Translation 
Initiation Factor 4E 
binding protein
NM_004096.4 Predicted Regulation of protein production through these gene products  
have been implicated in beta-cell proliferation (40, 41)
IRS-4 Insulin receptor  
substrate 4
NM_003604.2 Predicted Involved in cell growth and glucose homeostasis (42, 43)
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been observed as mediators of tissue crosstalk, acting both in 
physiological conditions as well as in diseases, thus being sug-
gested as new “hormones” (45). Consequently, investigating 
circulating miRNAs expression may potentially reveal both 
new biomarkers of disease as well as suggest new pathogenic 
mechanisms.
Regarding GDM, two previous studies analyzed circulating 
miRNAs expression profiles in plasma and serum, adopting 
high-throughput techniques. However, the results between the 
two studies were discordant, possibly due to different types of 
biological samples analyzed (serum vs plasma) as well as poten-
tial differences in pre-analytical sample processing (46). Indeed, 
miRNAs expression in serum or plasma is strongly influenced by 
small changes in pre-analytical steps and several strict guidelines 
need to be followed in order to reduce variability across samples 
and to finally identify reliable biomarkers (47). In the present 
study, we analyzed the expression profile of 384 miRNAs in plasma 
samples derived from non-diabetic pregnant women and GDM 
pregnant patients with the aim: (i) to detect new biomarkers of 
gestational diabetes; (ii) to suggest new pathogenic mechanisms 
leading to gestational diabetes onset. Importantly, samples were 
collected using a standardized protocol specifically following all 
the necessary procedures to reliably identify potentially altered 
miRNA expression. A two-step analysis was adopted in order to 
identify differentially expressed miRNAs: (1) a high-throughput 
approach involving a selected subpopulation of GDM patients 
and CTR (age and BMI matched), followed by (2) an extended 
validation stage in an additional cohort aimed at characterizing 
the expression of single miRNAs previously detected in the first 
profiling step. Adopting such approach we finally confirmed 
the differential expression of miR-330-3p, which resulted sig-
nificantly upregulated in GDM plasma samples vs non-diabetic 
CTR. MiR-330-3p expression levels were inversely correlated to 
insulinemia and such correlation was restricted to GDM patient. 
These results may suggest a new potential connection between 
miR-330-3p expression and diabetic state. More interestingly, 
we identified two subpopulations of GDM patients characterized 
by different levels of miR-330-3p: GDM-miR-330high and GDM-
miR-330low. The GDM patients group retaining higher plasmatic 
levels of miR-330-3p showed signs of a more aggressive diabetic 
phenotype; indeed they were more likely to require future 
insulin therapy respect to GDM-miR-330low whose glycemic 
control was guaranteed by diet indications only; moreover, the 
rate of those GDM patients having one or more T2D relatives 
was higher in GDM-miR-330high (Table  3). Although such 
results were not statistically significant, a secondary indication 
of a worse diabetic outcome in GDM-miR-330high with respect 
to GDM-miR-330low was indirectly measured by cesarean sec-
tion rate [a gestational diabetic complication, strongly related 
to hyperglycemia and glycemic control during pregnancy (48)], 
which was significantly higher in GDM-miR-330high thus further 
confirm a correlation between miR-330-3p plasmatic levels and 
GDM outcome during pregnancy and reinforcing a potential 
view of miR-330-3p as an indicator of an aggressive diabetic 
phenotype. Overall, such results pointed out a potential role for 
miR-330-3p as a new biomarker of GDM outcome. One poten-
tial limit of this study is the small number of patients; however, 
the use of a specific and stringent procedure for blood drawn, 
plasma collection, and miRNAs analysis (previously reported as 
critical for low variance maintenance among samples), provided 
enough accuracy to obtain statistically significant results, at least 
for miRNA miR-330-3p. Therefore, although further studies are 
needed in order to deepen these results, the measurement of 
circulating levels of miR-330-3p may help in advance to guide 
the choice of a personalized therapy in GDM, being miR-330-3p 
circulating levels able to potentially predict diabetic outcome 
and/or severity.
Although circulating miRNAs could be used as new disease 
biomarkers, a potential role as mediators of tissue crosstalk has 
been assigned to their function. Indeed, several authors started 
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FigUre 5 | E2F1 Interaction networks analysis graph performed using Biogrid software tool. Interaction networks analysis between E2F1 and its reported protein 
interactors, show several factors involved in the control of proliferation. Yellow connection lines represent a physical interaction evidence while purple connection 
lines reports both a genetic and physical interaction. Only those interactions with three or more reported and published evidences are shown. Greater node size 
represents increased connectivity while thicker edges represent increased evidences. Red rectangles highlight interactors with a previously described role in 
beta-cell function.
to link circulating miRNAs alterations as a putative disruption 
of a communication track among tissues/cells. Therefore, we 
hypothesized that the alteration of miR-330-3p expression levels 
in plasma of GDM patients may be involved in the loss of compen-
satory potential by beta-cells during pregnancy, thus contributing 
to GDM onset. miR-330-3p has been previously demonstrated 
to be active as a cell cycle suppressor during cancer; indeed, the 
alteration of its expression may cause changes in proliferation and 
growth thus rendering it a pivotal regulator of cell cycle homeo-
stasis. It is conceivable that miR-330-3p upregulation in plasma of 
GDM patients, if transferred to beta-cells, may partly contribute 
to beta-cell dysfunction thus causing defects in proliferation and 
growth. Indeed, miR-330-3p target genes search using both algo-
rithms for previously experimentally validated targets and those 
for the prediction revealed that E2F1 and CDC42 are miR-330-3p 
target genes. Both have been previously demonstrated to be 
involved in beta-cell proliferation and growth and, moreover, 
strong evidences indicated them as involved in the control of 
insulin secretion. Therefore, the reduction of E2F1 and CDC42, 
potentially caused by increased levels of miR-330-3p, may lead to 
an impairment of beta-cell proliferation and insulin secretion. In 
support of this hypothesis, it has been previously demonstrated 
that cell cycle genes are necessary to beta-cell compensatory 
adaptation during pregnancy, being 67 those genes involved in 
proliferation control and upregulated in pregnant mouse islets 
(49, 50), and that the disruption of their network may cause mas-
sive defects in beta-cell adaptation mechanisms. Additionally, 
beside the control of beta-cell proliferation, Targetscan7.0 miR-
330-3p predicted targets, revealed several other genes potentially 
involved in beta-cell function such as AGTR2 (Angiotensin II 
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FigUre 6 | CDC42 Interaction networks analysis graph performed using Biogrid software tool. Interaction networks analysis between CDC42 and its reported 
protein interactors, show several factors involved in the control of proliferation. Yellow connection lines represent a physical interaction evidence while purple 
connection lines reports both a genetic and physical interaction. Only those interactions with three or more reported and published evidences are shown. Greater 
node size represents increased connectivity while thicker edges represent increased evidences. Red rectangles highlight interactors with a previously described role 
in beta-cell function.
receptor Type 2) [which partially CTR beta-cell differentiation 
(37, 38)] or EIF4EBP2 [involved in beta-cell proliferation and 
differentiation (40)]. Of particular interest, AGTR2 has been 
previously demonstrated to be an active factor which exploits its 
function during pancreas development at embryonic stage, but 
also addressed as potential mediator of beta-cell regeneration 
in adult pancreas; it is possible to hypothesize that high plasma 
levels of miR-330-3p may inhibit pancreatic endocrine/beta-cell 
neogenesis through the downregulation of AGTR2 expression, 
thus determining a defect in the regenerative capacity of endo-
crine pancreas during high metabolic requirements.
Finally, one potential open question remains about deter-
mination of circulating miR-330-3p tissue/cells of origin; such 
information could be of fundamental importance in order to 
address whether a specific “mirroring” plasma-tissue may be 
identified. By interrogating several miRNAs expression databases 
reporting their high-throughput expression in several human tis-
sues, we found that miR-330-3p resulted enriched in breast tissue 
respect to the other tissues analyzed. Although such data need 
to be confirmed by other independent observations, a potential 
indication about its primary derivation sites has been raised, 
thus opening to the possibility of a miRNA-mediated crosstalk 
between breast tissue and endocrine pancreas during normal and 
diabetes-complicated pregnancy.
In conclusion, we demonstrated that miRNA miR-330-3p 
is upregulated in plasma of GDM patients and identifies a 
subgroup of those patients with a more adverse course of ges-
tational diabetes. Finally, we suggest that miR-330-3p could be 
potentially used both as a biomarker of GDM outcome as well 
as a therapeutic target. However, additional studies are needed 
to finally confirm the potential use of circulating miRNAs as 
biomarkers and to uncover their role as dysfunction mediators 
in GDM.
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